Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,705 total articles
Credo (CRDO) is trading like a hyper-growth story priced for perfection, yet the sell-side and short flows have overreacted to optics noise. Q1 FY2027 revenue of $479M (+114.7% YoY), an FY2027 optical revenue target north of $600M, seven quarters of triple-digit growth and a debt-free balance sheet create a buyable setup. This trade lays out entry,…
Micron is trading near $1,088 with tight supply dynamics for DRAM/HBM and strong free cash generation. Balance sheet strength, high ROE, and improving technicals create a favorable asymmetric trade. This is a tactical buy: entry $1,088, stop $940, target $1,500 over a mid-term 45 trading day horizon, risk medium.
Viking Holdings (VIK) trades at a premium multiple but reports robust booking metrics, sequential revenue beats and high forward occupancy that support a buy. We lay out a tactical long with clear entry, stop and target, anchored to strong Q2 results and 2026 booking cadence while flagging fuel, macro and valuation risks.
Micron's exposure to hyperscale and AI-heavy data centers, combined with improving fundamentals (EPS of $44.69, free cash flow $26.2B, ROE ~50%), supports a materially higher 2029 outlook than consensus. The stock is expensive on absolute multiples today but the market should assign a premium multiple as memory shifts from cyclical commodity to dur…
Core Scientific ($15.93) is trading near the low end of its 52-week range after a corrective stretch. Colocation revenue surged to $65M in 2025 from $24M in 2024, management secured near-term financing, and reports of AMD approval for hosting/AI workloads — if confirmed - materially de-risks capacity monetization. With a market cap near $5.12B and …
L3Harris (LHX) offers a pragmatic entry into the global rearmament cycle. The company combines predictable FCF, a $42B backlog, attractive dividend yield, and international expansion with a valuation that looks reasonable versus its cash flow profile. We upgrade to a buy and recommend a mid-term swing trade with clear entry, stop and target levels.
Almonty looks priced for a severe commodity collapse. We think that’s too pessimistic. Operational advances at Sangdong, a shallow global supply base, and steady industrial demand create a setup where upside from a modest recovery in tungsten prices materially outpaces downside. This trade targets that asymmetry with defined entry, stop and targets…
Elastic has pivoted from open-source search to a high-margin, AI-enabled cloud software vendor. Recent beats, accelerating Elastic Cloud sales, and improving profitability give the stock a credible growth-for-profit story. At a market cap near $9.8B and a P/E around 26x, the risk-reward favors a long trade over the next 180 trading days if enterpri…
Booz Allen (BAH) trades cheaply for a company converting strong free cash flow while sitting squarely in defense and cyber niches that stand to benefit from rising federal budgets. Near-term revenue churn and cautious consensus keep the stock muted—an opportunity to buy on weakness and target a re-rating toward industry multiples as catalysts line …
Alamar Biosciences is trading off a quick pullback after a recent run. The company’s instrument placements and accelerating consumables sales — highlighted by record Q1 revenue of $26.0M and major academic partnerships — argue for a durable revenue mix shift toward recurring, higher-margin assay sales. This trade idea buys the dip with a defined st…
Heritage Insurance (HRTG) looks attractively priced at about $34.55 with a P/E under 5, EV/EBITDA ~1.68 and implied net cash on the balance sheet. Underwriting discipline has driven profitability higher and free cash flow is large relative to market cap. This trade idea lays out an entry, stop and target along with catalysts and risks for a mid-to-…
Porsche AG is investing aggressively to electrify and expand its model range. That strategic reset improves its medium-term positioning but creates a narrow window of margin pressure and execution risk into 2027. We favor a tactical short: enter at $78.00, stop at $92.00, and target $55.00 over a long-term horizon (180 trading days).
CHAD offers a near-14% distribution and a yield model tied to crypto-native revenue sources (staking, lending income and protocol fees). This trade idea buys optionality: income today with upside if crypto markets and protocol economics cooperate. We set a clear entry, stop and target and outline the catalysts and the risks that would change the vi…
McDonald's is trading near its 52-week low despite strong cash flow generation, a 3.2% dividend yield, and a concrete $8.5B modernization plan. Same-store sales headlines have dominated the narrative, but they understate the company's cash-producing franchise model, margin resilience, and optionality from beverages and advertising. This trade targe…
Valero (VLO) looks stretched: fundamentals show outsized, cyclical profitability and high ROE while technicals and positioning signal vulnerability. We present a mid-term (45 trading days) short with precise entry, stop and target levels based on valuation re-pricing and catalysts that could expose margin weakness.
Marvell surged after its investor day as management raised FY2028 revenue guidance to $20B and outlined a $70-90B target by FY2031. That reset turns Marvell from a cyclically exposed semiconductor name into a high-growth AI infrastructure play. The trade: enter on a measured pullback, size for conviction, use a disciplined stop and target a materia…
Frontdoor's recent quarters show durable margin improvement driven by higher gross profit margins, stronger free cash flow and successful M&A integration. At current levels, the stock offers a reasonable risk/reward given a 7%+ free cash flow yield, EV/EBITDA of 11.6 and a clear path to earnings and cash conversion. Trade plan provided for a long p…
BE Semiconductor (BESI) sits squarely in the path of the HBM-driven packaging wave. Orders historically arrive after qualification windows; this trade buys ahead of that inflection, with a clearly defined stop and two-stage target plan tied to order cadence and visible backlog improvements.
The mobility spin-off simplified S&P Global’s portfolio and concentrated cash flow in higher-margin, recurring products. That structural change, combined with steady demand for benchmark data and ratings, sets up a tactical long trade aiming to capture a re-rating as investors re-underwrite growth and free cash flow.
Novo Nordisk has been punished for near-term earnings and revenue downgrades, yet the stock trades at a single-digit P/E with a healthy yield and technical support near oversold levels. This trade buys into a re-rating scenario against its higher-growth peer while acknowledging meaningful competitive and execution risks.
ASML is trading above its short-term moving averages, carries strong margin profiles and has upbeat analyst expectations for Q3. With a market cap near $703.5B and near-term catalysts tied to EUV demand for AI chips, the setup looks actionable for a swing trade into post-earnings rotation. Entry, stop and target are provided with a clear time horiz…
Astec Industries (ASTE) fell to a fresh low near $38.34 on 10/07/2026 after a recent run-up earlier this year. The sell-off has created a disciplined buying opportunity: the company shows improving margins, strong adjusted EBITDA momentum, a completed accretive acquisition, and an EV/EBITDA of ~11.9 that leaves upside if management executes. This t…
McDonald's (MCD) is trading near its 52-week low after a pullback that punished growth expectations. The business still generates durable free cash flow ($7.385B trailing FCF) and pays a healthy ~3.2% dividend. For traders willing to accept operational execution risk, a controlled long with a $231 entry, $260 target and $222 stop balances upside fr…
PMV Pharmaceuticals is a small-cap precision oncology company developing rezatapopt, a first-in-class reactivator of the TP53 Y220C mutation. With a 50% overall response rate reported from a 48-patient cohort, an NDA planned for Q1 2027, and a companion diagnostic partnership in place, the stock looks mispriced against the binary upside of regulato…
Oracle looks like a good swing-long after recent stabilization around $140. The business is benefitting from a huge contracted AI backlog, improving cloud revenue dynamics and still-high profitability metrics. Valuation at roughly $435B market cap and a mid-20s P/E leaves room for multiple expansion if execution continues. Trade plan provided with …
